Chardan Capital Reiterates Buy on Better Therapeutics, Maintains $9 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Better Therapeutics (NASDAQ:BTTX) and maintained a price target of $9.

August 10, 2023 | 8:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reiterated a 'Buy' rating on Better Therapeutics and maintained a price target of $9.
The reiteration of a 'Buy' rating by Chardan Capital indicates a positive outlook for Better Therapeutics. The maintained price target of $9 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100